Xcovery Overview
- Year Founded
-
2006
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
Later Stage VC
- Investors
-
2
Xcovery General Information
Description
Developer of novel therapies intended to build a pipeline of oncology medicines for malignant tumors. The company's small-molecule targeted oncology therapies eliminate the challenges associated with cancer treatment resistance, enabling patients to receive painless treatments.
Contact Information
Website
www.xcovery.comCorporate Office
- 168 Southeast 1st Street
- 11th Floor
- Miami, FL 33131
- United States
Corporate Office
- 168 Southeast 1st Street
- 11th Floor
- Miami, FL 33131
- United States
Xcovery Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 01-Nov-2023 | Completed | Clinical Trials - Phase 3 | |||
| 8. Merger/Acquisition | 01-Dec-2017 | Completed | Clinical Trials - Phase 3 | |||
| 7. Later Stage VC (Series E) | 26-Feb-2016 | Completed | Clinical Trials - Phase 3 | |||
| 6. Later Stage VC | 29-Oct-2014 | Completed | Clinical Trials - Phase 3 | |||
| 5. Later Stage VC (Series D) | 19-Jun-2014 | Completed | Clinical Trials - Phase 3 | |||
| 4. Later Stage VC (Series C) | 08-Apr-2014 | Completed | Clinical Trials - Phase 3 | |||
| 3. Later Stage VC (Series B) | 19-Sep-2012 | Completed | Clinical Trials - Phase 3 | |||
| 2. Later Stage VC (Series A) | 31-Oct-2011 | $2.42M | $3.91M | Completed | Clinical Trials - Phase 3 | |
| 1. Debt - General | 01-Oct-2010 | $1.49M | $1.49M | Completed | Clinical Trials - Phase 3 |
Xcovery Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 103,730 | $0.001000 | $29.19 | $29.19 | 1x | $29.19 | 5.36% | |
| Series A | 139,513 | $0.001000 | $14.3 | $14.3 | 1x | $14.3 | 7.21% |
Xcovery Comparisons
Industry
Financing
Details
Xcovery Competitors (48)
One of Xcovery’s 48 competitors is Sorrento Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| RAPT Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Cidara Therapeutics | Formerly VC-backed | San Diego, CA |
Xcovery Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Xcovery Patents
Xcovery Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-7054528-B2 | Crystal form of compound that suppresses protein kinase activity and its application | Active | 01-Jun-2016 | ||
| JP-2019518026-A | Crystal form of compound which inhibits protein kinase activity, and application thereof | Active | 01-Jun-2016 | ||
| AU-2017274110-A1 | Crystalline form of compound suppressing protein kinase activity, and application thereof | Active | 01-Jun-2016 | ||
| AU-2017274110-B2 | Crystalline form of compound suppressing protein kinase activity, and application thereof | Active | 01-Jun-2016 | ||
| CA-3026142-A1 | Crystalline form of compound suppressing protein kinase activity, and application thereof | Active | 01-Jun-2016 | C07D403/12 |
Xcovery Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Xcovery Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| China Resources Capital Management | Corporate Venture Capital | Minority | ||
| Brace Pharma Capital | Corporate Venture Capital | Minority |
Xcovery Acquisitions (1)
Xcovery’s most recent deal was a Merger/Acquisition with Meryx. The deal was made on 07-Dec-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Meryx | 07-Dec-2021 | Merger/Acquisition | Drug Discovery |
Xcovery FAQs
-
When was Xcovery founded?
Xcovery was founded in 2006.
-
Where is Xcovery headquartered?
Xcovery is headquartered in Miami, FL.
-
What is the size of Xcovery?
Xcovery has 16 total employees.
-
What industry is Xcovery in?
Xcovery’s primary industry is Drug Discovery.
-
Is Xcovery a private or public company?
Xcovery is a Private company.
-
What is Xcovery’s current revenue?
The current revenue for Xcovery is .
-
How much funding has Xcovery raised over time?
Xcovery has raised $54M.
-
Who are Xcovery’s investors?
China Resources Capital Management and Brace Pharma Capital have invested in Xcovery.
-
Who are Xcovery’s competitors?
Sorrento Therapeutics, RAPT Therapeutics, Ayala Pharmaceuticals, NGM Biopharmaceuticals, and Cidara Therapeutics are some of the 48 competitors of Xcovery.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
